Enhanced antitumor effects of hTRAIL by binding to endogenous albumin

Journal of Controlled Release

Volumn 228, Issue , 2016, Pages 206-

  Park, Kinam ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; HUMAN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; HYBRID PROTEIN; PROTEIN BINDING; SERUM ALBUMIN; TNFSF10 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CIRCULATING TUMOR CELL; CYTOTOXICITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; EDITORIAL; HUMAN; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; METABOLISM; MOUSE; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; NEOPLASMS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84962676167     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.03.033     Document Type: Editorial

References (3)

1. B. Elsadek, and F. Kratz Impact of albumin on drug delivery-new applications on the horizon J. Control. Release 157 2012 4 28
2. R. Li, H. Yang, D.L. Jia, Q.X. Nie, H.W. Cai, Q. Fan, L. Wan, L. Li, and X.F. Lu Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL J. Control. Release 228 2016 96 106
3. J. Li, C.C. Sharkey, B. Wun, J.L. Liesveld, and M.R. King Genetic engineering of platelets to neutralize circulating tumor cells J. Control. Release 228 2016 38 47